Humanized Anti-Factor D Antibodies And Uses Thereof
US-2015376295-A1 · Dec 31, 2015 · US
Monoclonal antibodies against antithrombin β
US9593166B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9593166-B2 |
| Application number | US-201414214382-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2014 |
| Priority date | Mar 14, 2013 |
| Publication date | Mar 14, 2017 |
| Grant date | Mar 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin β complexed with heparin and/or heparin-like structure (ATβH). These ATβH binding proteins can block the anti-coagulant activity of ATβ to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.
First claim
Opening claim text (preview).
We claim: 1. A monoclonal antibody capable of binding AtβH, wherein the heavy chain of said antibody comprises: a HCDR1 comprising SEQ ID NO: 40, a HCDR2 comprising SEQ ID NO: 45, and a HCDR3 comprising SEQ ID NO: 50; and wherein the light chain of said antibody comprises: a LCDR1 comprising SEQ ID NO: 21, a LCRD2 comprising SEQ ID NO: 26, and a LCDR3 comprising SEQ ID NO: 31.
Assignees
Inventors
Classifications
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
against protease inhibitors of peptide structure · CPC title
Fab or Fab' · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9593166B2 cover?
- This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin β complexed with heparin and/or heparin-like structure (ATβH). These ATβH binding proteins can block the anti-coagulant activity of ATβ to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods o…
- Who is the assignee on this patent?
- Bayer Healthcare Llc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/36. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).